



CSL Research Acceleration Initiative

Applications close 12th March 2021

WHY COLLABORATE WITH CSL?



Global Capabilities on your doorstep



Work with one of the world's leading biotech companies



Funding for successful proposals




Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise



Accelerate translation of your research to deliver new therapies to patients

CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations.

The 2021 Research Acceleration Initiative will focus on research proposals that align with a **CSL Therapeutic Area** and are amenable to or include a **Modality** as illustrated below. Please see over page for specific **Focus Areas**.



Successful applicants will receive up to \$250k p.a. for up to 2 years (max \$500k funding).

Researchers who wish to apply are required to submit a 300 word online pre-application by **12th March 2021**. Shortlisted applicants will then be invited to submit a detailed proposal in April.


To **apply** please email jerome.wielens@unimelb.edu.au

Interested researchers are invited to join an online information session to learn more. Webinars will be held: **Tues 9th Feb, 2pm – 3pm AEDT** OR **Fri 12th Feb, 12pm – 1pm AEDT**
For webinar links and online application instructions please e-mail jerome.wielens@unimelb.edu.au

CSL Research Acceleration Initiative

Focus Areas

CSL is seeking applications in the following **Focus Areas**:



Focus Areas	Autoimmune diseases	Sickle cell disease	Interstitial lung diseases	Rare lipid disorders	Tolerance
	Novel biologic targets/therapeutics or strategies to understand pathomechanisms of: <i>Sjögren's syndrome, Systemic sclerosis, SLE, Pemphigus vulgaris, Hidradenitis suppurativa, Dermatomyositis, other rare rheumatological/dermatological conditions</i>	Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy	Novel biologic targets/therapeutics	(e.g. Familial hypercholesterolemia, Familial chylomicronemia) In vivo gene-editing and technologies for liver targeted delivery	(Solid organ transplant/HSCT) Novel strategies or biologics to induce tolerance (T regs, T cell anergy and/or tolerogenic DCs)
	Inflammation Novel strategies to modulate the immune system to treat inflammatory diseases (including neuroinflammation e.g. CIDP)	Ischemic and hemorrhagic stroke Novel biologic targets/therapeutics or strategies to understand pathomechanisms	Biomarker/Omics approaches for patient stratification and drug discovery	Severe forms of atherosclerosis Novel biologic targets/therapeutics or strategies to understand pathomechanisms	Graft vs host disease Novel biologic targets/therapeutics to modulate the immune response for treatment and prevention
	Next generation IVIG / alternatives to plasma-derived IVIG	Focus on neuro- and thrombo-inflammation/ novel thrombolytics	Novel animal and human disease models	Refractory angina Novel biologic targets/therapeutics	Acute rejection (Antibody-mediated rejection) Novel biologic targets/therapeutics to modulate the immune response
		Biomarker/Omics approaches for patient stratification and drug discovery	Acute respiratory distress syndrome Novel biologic targets/therapeutics	Myocarditis Novel biologic targets/therapeutics	Hematopoietic stem cell transplants Strategies to improve efficacy/ safety, including inducing stem cell mobilisation, reducing toxicity of BM conditioning, improvement of engraftment
		Hemophilia <i>In vivo</i> gene-editing and technologies for liver targeted delivery	Biomarker/Omics approaches for patient stratification and drug discovery	Novel animal and human disease models	
			Alpha-1 antitrypsin deficiency In vivo gene-editing and technologies for liver targeted delivery	Access to patient samples	

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail RAI@csl.com.au to discuss.